Affibody and Chiesi Group to develop treatments for respiratory diseases
Affibody AB and Chiesi Farmaceutici S.p.A have announced a collaboration and licensing agreement to develop…
Affibody AB and Chiesi Farmaceutici S.p.A have announced a collaboration and licensing agreement to develop…
INOVIO Pharmaceuticals has announced positive preliminary results from the second cohort of its phase 1/2…
Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial…
Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic…
Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development announced today significant results…
C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca. It is worth…
A new anti-virulence therapy, RESP-X, treating Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB)…
Verona Pharma plc has today (October 17) announced that it has entered into a debt…
Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for…
Beyfortus, which is being developed jointly by Sanofi and AstraZeneca, is a step closer to…
Synairgen plc is to collaborate on a University of Southampton study on acute respiratory viral…
A biopharmaceutical company developing vaccines against infectious diseases has announced positive results for people with…